• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Humanigen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits

    7/24/23 9:25:22 PM ET
    $HGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HGEN alert in real time by email
    0001293310 false 0001293310 2023-07-18 2023-07-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

     

     

    FORM 8-K

      

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 18, 2023

      

     

     

    Humanigen, Inc.
    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or other Jurisdiction of Incorporation)

    001-35798

    (Commission File No.)

    77-0557236

    (IRS Employer Identification No.)

     

    830 Morris Turnpike, 4th Floor

    Short Hills, New Jersey 07078
    (Address of principal executive offices and zip code)

     
    (973) 200-3010
    (Registrant's telephone number, including area code)
     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
       
      Securities registered pursuant to Section 12(b) of the Act:

     

      Title of each class

    Trading

    Symbol(s)

    Name of each exchange on which registered
      Common Stock HGEN The Nasdaq Stock Market LLC

     

      Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
      Emerging growth company ¨
      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

       
     

     

    Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As a result of the below-reported resignations of three members of the board of directors (the “Board”) of Humanigen, Inc. (the “Company”), the Company notified The Nasdaq Stock Market of the Company’s non-compliance with each of Nasdaq Rule 5605(b)(1), which requires a Nasdaq-listed company to have a board of directors comprised of a majority of independent directors; and Nasdaq Rule 5605(c)(2), which requires a Nasdaq-listed company to have an audit committee of the board of directors comprised of at least three independent directors meeting the eligibility requirements of that Rule.

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On July 18, 2023, John Hohneker resigned from the Board, and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect. The decisions of Dr. Hohneker, Ms. Buxton and Mr. Xie to resign were not the result of disagreements with Humanigen on any matter relating to Humanigen's operations, policies or practices.

     

    Item 8.01Other Events.

     

    Corporate Update

     

    The Company’s negotiations with a privately held biopharmaceutical company relating to a proposed business combination, as disclosed in the Company’s Quarterly Report on Form 10-Q filed on May 15, 2023, have ended without execution of a definitive agreement. In addition, the Company has been unsuccessful in its attempt to identify and complete another strategic or equity financing transaction in the first half of 2023 on terms sufficient to enable the Company to regain compliance with applicable Nasdaq listing requirements within the extended compliance period of August 21, 2023. The Company further has been unsuccessful in raising debt or equity financing in sufficient amounts and with acceptable terms to fund the Company’s operations going forward.

     

    In light of these developments and the matters discussed above under Item 3.01, on July 21, 2023, the Company notified the Nasdaq Hearings Panel (the “Panel”) that it does not expect to be able to demonstrate compliance with all applicable criteria for listing on The Nasdaq Capital Market by August 21, 2023, including the $1.00 minimum bid price per share requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company received a letter on the evening of July 24, 2023 indicating that the Panel will delist the shares of the Company from the Nasdaq Capital Market and trading in the Company shares will be suspended from Wednesday, July 26, 2023. The shares will commence trading on the OTC Pink Market. The suspension from trading and delisting from the Nasdaq Capital Market likely would adversely affect the liquidity of the Company’s common stock and its ability to raise additional capital.

     

    In light of the above, and the Company’s limited cash and cash equivalents, the Company anticipates that it will not be able to continue as a going concern and is exploring all restructuring options, which may include commencing a bankruptcy or other insolvency proceeding sometime in the third quarter of 2023. In that regard, the Company is evaluating term sheets relating to potential sales of assets in a bankruptcy proceeding. Given the Company’s lack of liquidity, any such bankruptcy filing may result in a complete or substantial loss of value for holders of our common stock.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)       Exhibits

     

    Exhibit
    No.

     

    Description

       
       
      104   Cover Page Interactive Data File (embedded within Inline XBRL document).

     

       
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

      HUMANIGEN, INC.
         
    Dated: July 24, 2023 By:   /s/ Cameron Durrant
      Name: Cameron Durrant
    Title: Chairman of the Board and Chief Executive Officer

     

     

     

     

     

     

     

     

    Get the next $HGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HGEN

    DatePrice TargetRatingAnalyst
    7/13/2022$13.00 → $2.00Buy → Neutral
    ROTH Capital
    7/13/2022$30.00 → $2.00Overweight → Neutral
    Cantor Fitzgerald
    7/13/2022Buy → Neutral
    H.C. Wainwright
    9/10/2021$9.00Buy → Hold
    Jefferies
    9/9/2021Outperform → Neutral
    Credit Suisse
    9/9/2021$36.00 → $28.00Buy
    H.C. Wainwright
    9/9/2021Neutral → Underweight
    JP Morgan
    8/13/2021$25.00 → $24.00Outperform
    Credit Suisse
    More analyst ratings

    $HGEN
    Financials

    Live finance-specific insights

    See more
    • Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

      Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021. The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7 Details about how to access the conference call and webcast are pr

      12/1/21 6:45:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/1/23 1:21:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Humanigen Inc. (Amendment)

      SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)

      3/17/22 4:28:37 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/14/22 4:54:04 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HGEN
    SEC Filings

    See more

    $HGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Humanigen downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Humanigen from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      7/13/22 9:07:33 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Humanigen from Overweight to Neutral and set a new price target of $2.00 from $30.00 previously

      7/13/22 7:40:18 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Humanigen from Buy to Neutral

      7/13/22 7:39:46 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      1/8/24 5:02:09 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Humanigen Inc.

      25-NSE - HUMANIGEN, INC (0001293310) (Subject)

      10/12/23 8:19:55 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      9/14/23 4:01:46 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      10/20/23 6:50:35 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hohneker John

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:06 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buxton Cheryl

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:07 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

      CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomono

      4/14/23 12:05:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Reports Third Quarter 2022 Financial Results

      Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway. The company is also contin

      11/14/22 4:01:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

      Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will be available and a webcast link to a recording of the event will be posted to the "Events and Presentations" section of Humanige

      11/10/22 8:02:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

      Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o

      9/1/22 7:00:00 AM ET
      $CLLS
      $HGEN
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

      Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo

      8/10/22 4:50:35 PM ET
      $AQST
      $DBVT
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

      BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen. Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of C

      6/7/21 8:00:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care